Advertisement

Novel APOB nonsense variant related to familial hypobetalipoproteinemia and hepatic steatosis: A case report and review

      Highlights

      • Familial hypobetalipoproteinemia is caused by monoallelic variants in APOB.
      • Metabolic Associated Fatty Liver Disease is the main associated comorbidity.
      • We report a novel APOB nonsense variant and present a short review about this entity.
      • We propose a support algorithm for the clinical diagnosis of this syndrome.

      Abstract

      Hereditary familial hypobetalipoproteinemia (FHBL) is a syndrome caused by variants in the APOB gene, that cause a defect in the secretion and mobilization of liver lipids to peripheral tissues, associated with the synthesis of truncated ApoB100 apolipoproteins. This condition causes significant reduction in total cholesterol (TC), low-density lipoproteins (LDL), very low-density proteins (VLDL) and serum triglyceride levels, with unchanged high-density lipoprotein (HDL) cholesterol levels. Herein we present the case of a middle-aged woman diagnosed with FHBL and hepatic steatosis, heterozygous for c.4698C>A; (p.Tyr1566Ter) variant in APOB. The variant presented herein showed high expressiveness in the two generations of individuals analyzed and has not yet being described in the medical literature. Early diagnosis and screening for associated metabolic comorbidities such as metabolic fatty liver disease and its subsequent progression to fibrosis are the two main goals in the treatment of this condition, in order to prevent medium to long term potential complications.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Clinical Lipidology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Burnett JR
        • Hooper AJ
        • Hegele RA
        • et al.
        APOB-related familial hypobetalipoproteinemia.
        in: Adam MP Ardinger HH Pagon RA GeneReviews® [Internet]. University of Washington, Seattle, SeattleWA2021 May 13 (1993-202)
        • Hooper A
        • Burnett J.
        Update on primary hypobetalipoproteinemia.
        Curr Atheroscler Rep. 2014; 16
        • Rimbert A
        • Vanhoye X
        • Coulibaly D
        • Marrec M
        • Pichelin M
        • Charrière S
        • et al.
        Phenotypic differences between polygenic and monogenic hypobetalipoproteinemia.
        Arterioscler Thromb Vasc Biol. 2020; https://doi.org/10.1161/ATVBAHA.120.315491
        • Kanwal F
        • Shubrook J
        • Adams L
        • Pfotenhauer K
        • Wai-Sun Wong V
        • Wright E
        • et al.
        Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease.
        Gastroenterology. 2021; 161: 1657-1669https://doi.org/10.1053/j.gastro.2021.07.049
        • Blanco-Vaca F
        • Martin-Campos J
        • Beteta-Vicente Á
        • Canyelles M
        • Martínez S
        • Roig R
        • et al.
        Molecular analysis of APOB, SAR1B, ANGPTL3, and MTTP in patients with primary hypocholesterolemia in a clinical laboratory setting: Evidence supporting polygenicity in mutation-negative patients.
        Atherosclerosis. 2019; 283: 52-60https://doi.org/10.1016/j.atherosclerosis.2019.01.036
        • Richards S
        • Aziz N
        • Bale S
        • Bick D
        • Das S
        • Gastier-Foster J
        • et al.
        Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
        Genet Med. 2015; 17: 405-424https://doi.org/10.1038/gim.2015.30
        • Rimbert A
        • Pichelin M
        • Lecointe S
        • Marrec M
        • Le Scouarnec S
        • Barrak E
        • et al.
        Identification of novel APOB mutations by targeted next-generation sequencing for the molecular diagnosis of familial hypobetalipoproteinemia.
        Atherosclerosis. 2016; 250: 52-56https://doi.org/10.1016/j.atherosclerosis.2016.04.010
        • Bredefeld C
        • Peretti N
        • Hussain M
        • Di Filippo M
        • Granot E
        • Cuerq C
        • et al.
        New classification and management of abetalipoproteinemia and related disorders.
        Gastroenterology. 2021; 160: 1912-1916https://doi.org/10.1053/j.gastro.2020.11.040
        • Di Costanzo A
        • Di Leo E
        • Noto D
        • Cefalù A
        • Minicocci I
        • Polito L
        • et al.
        Clinical and biochemical characteristics of individuals with low cholesterol syndromes: A comparison between familial hypobetalipoproteinemia and familial combined hypolipidemia.
        J Clin Lipidol. 2017; 11: 1234-1242https://doi.org/10.1016/j.jacl.2017.06.013
        • Welty F
        Hypobetalipoproteinemia and abetalipoproteinemia.
        Curr Opin Lipidol. 2014; 25: 161-168https://doi.org/10.1097/MOL.0000000000000072
        • Buryska S
        • Ahn J
        • Allen A
        • Simha V
        • Simonetto D
        • Hypobetalipoproteinemia Familial
        An underrecognized cause of lean NASH.
        Hepatology. 2021; 74: 2897-2898https://doi.org/10.1002/hep.31988
        • Cefalù A
        • Pirruccello J
        • Noto D
        • Gabriel S
        • Valenti V
        • Gupta N
        • et al.
        A novel APOB mutation identified by exome sequencing cosegregates with steatosis, liver cancer, and hypocholesterolemia.
        Arterioscler Thromb Vasc Biol. 2013; 33: 2021-2025https://doi.org/10.1161/ATVBAHA.112.301101
        • Ayoub C
        • Azar Y
        • Abou-Khalil Y
        • Ghaleb Y
        • Elbitar S
        • Halaby G
        • et al.
        Identification of a variant in APOB gene as a major cause of hypobetalipoproteinemia in Lebanese families.
        Metabolites. 2021; 11: 564https://doi.org/10.3390/metabo11090564
        • Angulo P
        • Kleiner D
        • Dam-Larsen S
        • Adams L
        • Bjornsson E
        • Charatcharoenwitthaya P
        • et al.
        Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease.
        Gastroenterology. 2015; 149 (e10): 389-397https://doi.org/10.1053/j.gastro.2015.04.043
        • Noto D
        • Arca M
        • Tarugi P
        • Cefalù A
        • Barbagallo C
        • Averna M.
        Association between familial hypobetalipoproteinemia and the risk of diabetes. Is this the other side of the cholesterol–diabetes connection? A systematic review of literature.
        Acta Diabetol. 2016; 54: 111-122https://doi.org/10.1007/s00592-016-0931-4
        • Musialik J
        • Boguszewska-Chachulska A
        • Pojda-Wilczek D
        • Gorzkowska A
        • Szymańczak R
        • Kania M
        • et al.
        A rare mutation in The APOB gene associated with neurological manifestations in familial hypobetalipoproteinemia.
        Int J Mol Sci. 2020; 21: 1439https://doi.org/10.3390/ijms2104